Verdiva Bio
Tapan Maniar is a seasoned professional in biotechnology and pharmaceuticals, currently serving as the Chief Business Officer and Co-Founder at Verdiva Bio since October 2024. Prior to this role, Tapan held similar positions at Aiolos Bio, and contributed as a Board Observer for Emalex Biosciences and Rivus Pharmaceuticals. Tapan has significant experience from Bain Capital as a Principal, and led business development efforts at Genentech, focusing on technology platforms and partnerships across therapeutic areas. Earlier career milestones include roles at McKinsey & Company as an Engagement Manager and Associate, as well as a Postdoctoral Associate at Rockefeller University. Tapan earned a Ph.D. in Neuroscience from The Rockefeller University and a B.A. in Biology from Bard College.
This person is not in any teams
This person is not in any offices
Verdiva Bio
1 followers
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.